Laurel A. Menapace/LinkedIn
Aug 2, 2026, 09:04
Laurel A. Menapace: Investing in the Next Generation of Hematology Leaders
Laurel A. Menapace, Former Senior Clinical Research Director of Rare Blood Disorders, Fitusiran Development Program at Sanofi, shared a post on LinkedIn:
“Thoroughly enjoyed participating in ISTH’s ECC Networking with Industry Session.
Some of the best career advice I’ve received has come from people willing to share their experiences openly.
I’m grateful for the opportunity to pay that forward and discuss career paths, clinical development, industry partnerships, and the many ways we can continue advancing therapies for patients.
Building the future of hematology requires more than great science—it requires investing in the people who will lead it.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines